IgA肾病患者体液生物标志物的研究进展  

Research Progress of Humoral Biomarkers in Patients with IgA Nephropathy

作　　者：孟钱 曹英杰[2] MENG Qian;CAO Yingjie(Nantong University,Nantong 226019,China;Department of Nephrology,Affiliated Hospital of Nantong University,Nantong 226001,China)

机构地区：[1]南通大学,江苏南通226019 [2]南通大学附属医院肾脏内科,江苏南通226001

出　　处：《医学综述》2024年第24期2961-2968,共8页Medical Recapitulate

基　　金：南通市科技项目(JC2021138)。

摘　　要：IgA肾病是我国终末期肾病的重要病因,也是我国近年肾脏病学研究的重点和难点。IgA肾病起病隐匿,早期临床症状轻微甚至无症状,漏诊率极高,肾穿刺活检具有侵入性,是目前诊断IgA肾病的唯一金标准。单一疗法虽然对IgA肾病有一定作用,但并不是对所有IgA肾病患者有效,而多靶点治疗在IgA肾病治疗中发挥重要作用。因此,研究体液生物标志物与IgA肾病之间的关系对于寻找IgA肾病的非侵入性诊断因子及其个性化治疗、判断预后有重要意义。IgA nephropathy is an important cause of end-stage renal disease in China,and it is also a key and difficult point in recent years of nephrology research in China.IgA nephropathy has an insidious onset,with mild or even asymptomatic early clinical symptoms and a high rate of missed diagnosis.Renal biopsy is invasive and currently the only gold standard for diagnosing IgA nephropathy.Although monotherapy has a certain effect on IgA nephropathy,it is not effective for all IgA nephropathy patients,while multi-target therapy plays an important role in IgA nephropathy treatment.Therefore,studying the relationship between body fluid biomarkers and IgA nephropathy is of great significance for finding non-invasive diagnostic factors for IgA nephropathy,individualized treatment,and predicting prognosis.

关 键 词：IGA肾病 半乳糖缺乏的IgA1 甘露糖结合凝集素 血清IgA/C3比值 肿瘤坏死因子-α 可溶性转铁蛋白 肾损伤分子-1 甘氨酸 

分 类 号：R692.31[医药卫生—泌尿科学]